Insights on Evolving Treatment Strategies for Multiple Myeloma

While bispecific antibodies tend to be well-tolerated for patients with multiple myeloma, there are still adverse effects clinicians should discuss with their patients.

Beth Finley-Oliver, MSN, ARNP, AGNP-BC, recaps part of her presentation from the 2023 JADPRO meeting about caring for patients with high-risk multiple myeloma.

At a recent Community Case Forum, an expert discussed the risk of cytokine release syndrome after patients undergo CAR T-cell therapy.

Beth Faiman, PhD, CNP, discusses reclassifying patients with multiple myeloma, the accelerated approval of teclistamab, and the removal of belantamab mafodotin from the US market.

An indirect comparison found that cilta-cel may be better than standard of care for patients with lenalidomise-refractory relapsed/refractory myeloma.

“Treatment effectiveness can have different meanings to patients,” a physician assistant said when discussing therapy for high-risk myeloma.